PT-141 testing round-up: what our latest samples measured
6 independently tested samples across 5 companies, and what the results say about PT-141.
The Peptide Institute Testing Desk··9 min read
PT-141 is a melanocortin receptor agonist with a development status of "fda-approved (branded form)". The Institute rates the strength of its published evidence as strong. A melanocortin agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
This report covers the PT-141 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 6 PT-141 samples from 5 companies. 83% met their label claims on purity and content. Measured purity ranged from 95.1% to 99.3%, averaging 97.7%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
